

NantHealth, NantKwest and NantOmics Announce Availability of GPS Cancer™ and Phase I – III QUILT Trials Through the U.S. National Institutes of Health's ClinicalTrials.gov

December 8, 2016

Patients and physicians can now access active clinical trials for various cancer types including lung, breast, leukemia and more through the largest clinical trials database

CULVER CITY, Calif.--(BUSINESS WIRE)-- [NantHealth](#), Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, together with NantKwest and NantOmics, today announced the public availability of QUILT Programs (Quantum Immunology Lifelong Trial), aimed to harness and orchestrate all elements of the immune system through the testing of novel treatment combinations, within the national clinical trials database, www.ClinicalTrials.gov.

QUILT utilizes [GPS Cancer](#) - a unique, comprehensive set of tests integrating quantitative proteomics, and whole genome (DNA) and transcriptome (RNA) sequencing—to provide oncologists with a full molecular profile of each patient's cancer not only for an initial biopsy before the trial begins, but throughout the trial process to fully understand how each therapy impacts the patient's tumor activity.

“The accessibility of QUILT trials through the NIH ClinicalTrials.gov registry allows us to better inform patients and healthcare providers about immunotherapy based trials now available and enrolling for a variety of cancers,” stated Dr. Patrick Soon-Shiong, CEO of NantHealth. “Registering the QUILT trials to ClinicalTrial.gov enables NantHealth to provide timely updates and summary results, ensuring that these active clinical trials are publicly available to accelerate immunotherapy treatments for both patients and oncologists.”

ClinicalTrials.gov is a registry of clinical trials run by the United States National Library of Medicine (NLM) at the National Institutes of Health (NIH), and is the largest clinical trials database, currently holding registrations from about 200,000 trials from more than 170 countries in the world. Trials are accepted by the NIH based on apparent validity, logic and consistency, and overall configuration.

To find a QUILT clinical trial, visit: <https://clinicaltrials.gov/ct2/results?term=QUILT&Search=Search>.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the capabilities and anticipated utility of our GPS Cancer, including predicting patient response and resistance to therapeutics, enabling diagnoses by physicians and accelerating efforts to bring novel combinations of therapeutic agents to cancer patients. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated

results. Factors that may cause future results to differ materially from management's current expectations include, among other things, that GPS Cancer may not perform as anticipated, that sufficient physicians may not adopt GPS Cancer to assist their diagnoses or that healthcare payers may not provide reimbursement for GPS Cancer as expected. Our business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of our products; our ability to successfully launch new products and applications; competition; our sales, marketing and distribution capabilities; our planned sales, marketing, and research and development activities; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting our business and operating results can be found in our existing and future filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements except as may be required by law.

About NantHealth, Inc.

NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine. For nearly a decade, NantHealth has developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets billions of molecular, clinical, operational and financial data points derived from novel and traditional sources, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time. For more information please visit www.nanthealth.com and follow Dr. Soon-Shiong on Twitter [@DrPatSoonShiong](https://twitter.com/DrPatSoonShiong).

About GPS Cancer™

GPS Cancer™ is a comprehensive molecular profile available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with unprecedented insight into the molecular signature of each patient's cancer to inform personalized treatment strategies. GPS Cancer profiling is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for the QUILT programs. For more information, visit www.gpscancer.com.



View source version on [businesswire.com](http://www.businesswire.com/news/home/20161208005293/en/): <http://www.businesswire.com/news/home/20161208005293/en/>

Media Contact

NantWorks

Jen Hodson, 562-397-3639

johodson@nantworks.com

Source: NantHealth, Inc.